Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Molecular Interactions Identified That Block Protein Transfer into Mitochondria of Huntington's Disease Neurons

By LabMedica International staff writers
Posted on 08 Jul 2014
Researchers have identified a protein complex that interacts with the mutated form of huntingtin protein to impair transport of proteins into the mitochondria of brain cells, which leads to their malfunction and the loss of neurons that characterizes Huntington's disease.

Huntington’s disease is caused by a dominant gene that encodes a protein known as huntingtin (Htt). More...
The 5' end of the Huntington's disease gene has a sequence of three DNA bases, cytosine-adenine-guanine (CAG), coding for the amino acid glutamine, that is repeated multiple times. Normal persons have a CAG repeat count of between 7 and 35 repeats, while the mutated form of the gene has anywhere from 36 to 180 repeats. The mutant form of Htt is broken down into toxic peptides, which contribute to the pathology of the syndrome.

Investigators at the Washington University School of Medicine (St. Louis, MO, USA) and their colleagues at the University of Pittsburgh (PA, USA) worked with in vitro culture models and with a mouse model that mimicked the early stages of Huntington's disease.

They reported in the May 18, 2014, online edition of the journal Nature Neuroscience that recombinant mutant Htt directly inhibited mitochondrial protein import in their culture model. Furthermore, mitochondria from the brain synaptosomes of presymptomatic Huntington's disease model mice and from mutant Htt-expressing primary neurons exhibited a protein import defect, suggesting that deficient protein import was an early event in Huntington's disease.

At the molecular level, the investigators spotted interactions between mutant Htt and the TIM23 (translocase of inner mitochondrial membrane 23) mitochondrial protein import complex. Overexpression of TIM23 complex subunits attenuated the mutant Htt–induced mitochondrial import defect and subsequent neuronal death, which demonstrated that deficient mitochondrial protein import caused mutant Htt-induced neuronal death.

“We showed the problem could be fixed by making cells overproduce the proteins that make this transfer possible,” said first author Dr. Hiroko Yano, assistant professor of neurological surgery, neurology, and genetics at the Washington University School of Medicine. “We do not know if this will work in humans, but it is exciting to have a solid new lead on how this condition kills brain cells.”

Related Links:

Washington University School of Medicine
University of Pittsburgh 



Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Pipette
Accumax Smart Series
Sample Transportation System
Tempus1800 Necto
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.